A carregar...
CD36: a key mediator of resistance to HER2 inhibitors in breast cancer
Acquired resistance to anti-HER2 therapy is a significant clinical challenge in breast cancer. We recently discovered that during acquisition of resistance to HER2 inhibition, upregulation of the fatty acid transporter CD36 takes place, playing a key role in metabolic rewiring and resistance to anti...
Na minha lista:
| Publicado no: | Mol Cell Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7051136/ https://ncbi.nlm.nih.gov/pubmed/32158927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2020.1715766 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|